BioGaia AB (BIOG B)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:BioGaia AB (BIOG B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012298
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), straws and infant formulas. BioGaia’s products are based on various strains of Lactobacillus reuteri, its patented lactic acid bacterium. Its products improve the digestive and oral health of children and adults, and controls digestive problems such as colic, regurgitation, diarrhea and constipation. The company’ sells its products through distributors in the Americas, Europe and Asia-Pacific. BioGaia is headquartered in Stockholm, Sweden.

BioGaia AB (BIOG B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
BioGaia AB, Medical Devices Deals, 2011 to YTD 2017 10
BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BioGaia AB, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13
BioGaia Enters into Agreement with Laboratorios Silanes 14
BioGaia Enters Into Distribution Agreement With Ache Labs 15
BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 16
BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 17
BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 18
BioGaia Enters Into Distribution Agreement With United Labs 19
BioGaia Enters Into Co-Marketing Agreement With Laboratoires Pharmaceutiques GALENICA 20
Licensing Agreements 21
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 21
BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22
BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23
BioGaia Enters Into Licensing Agreement With Nestle 24
Equity Offering 25
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 25
Infant Bacterial Therapeutics to Raise up to USD52.4 Million in Rights Offering of Shares 27
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 29
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 30
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 31
Acquisition 32
BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32
BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33
BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34
BioGaia To Acquire Remaining 50% Stake In TwoPac For US$4.6 Million 35
BioGaia AB – Key Competitors 36
BioGaia AB – Key Employees 37
BioGaia AB – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Strategy And Business Planning 40
Jun 21, 2017: BioGaia sets up subsidiary for the development of probiotic drugs 40
Financial Announcements 41
Aug 18, 2017: BioGaia Interim report 1 January – 30 June 2017 41
May 03, 2017: BioGaia – Interim management statement 1 January – 31 March 2017 42
Feb 10, 2017: BioGaia – Year-end report 2016 43
Oct 25, 2016: BioGaia: Interim management statement 1 January – 30 September 2016 44
Aug 17, 2016: BioGaia – Interim report 1 January – 30 June 2016 45
May 10, 2016: BioGaia: Interim management statement 1 January – 31 March 2016 46
Apr 27, 2016: BioGaia: IBT’s Results for the First Quarter of 2016 47
Feb 12, 2016: BioGaia – Year-end report 2015 48
Government and Public Interest 49
Aug 08, 2016: BioGaia: BioGaia’s Oral Health Probiotic Reduces Pregnancy Gingivitis 49
Product News 50
May 17, 2016: BioGaia’s Probiotic Effective in Treating Abdominal Pain in Children 50
Other Significant Developments 51
Sep 14, 2016: BioGaia’s probiotics to be launched in Kenya, Nigeria and Ghana 51
Apr 25, 2016: BioGaia’s oral health probiotics to be launched in Hong Kong 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
BioGaia AB, Pharmaceuticals & Healthcare, Key Facts, 2016 2
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
BioGaia AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
BioGaia AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
BioGaia AB, Deals By Therapy Area, 2011 to YTD 2017 9
BioGaia AB, Medical Devices Deals, 2011 to YTD 2017 10
BioGaia AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
BioGaia Extends Licensing Agreement With Nestle For Lactobacillus Reuteri 13
BioGaia Enters into Agreement with Laboratorios Silanes 14
BioGaia Enters Into Distribution Agreement With Ache Labs 15
BioGaia Enters Into Distribution Agreement With Dong Sung For Baby Drops And Tablets 16
BioGaia Enters Into Distribution Agreement With Dexcel Pharma For Oral Health Products 17
BioGaia Enters Into Distribution Agreement With Ferozsons Labs For Probiotic Drops And Tablets 18
BioGaia Enters Into Distribution Agreement With United Labs 19
BioGaia Enters Into Co-Marketing Agreement With Laboratoires Pharmaceutiques GALENICA 20
Infant Bacterial Therapeutics Enters into Licensing Agreement with BioGaia 21
BioGaia Enters Into Licensing Agreement With Nestle For Lactobacillus Reuteri 22
BioGaia Enters Into Licensing Agreement With Nestle Mexico For ProTectis 23
BioGaia Enters Into Licensing Agreement With Nestle 24
Infant Bacterial Therapeutics Raises USD18 Million in Private Placement of Shares 25
Infant Bacterial Therapeutics to Raise up to USD52.4 Million in Rights Offering of Shares 27
Infant Bacterial Therapeutics Raises USD12 Million in Rights Offering of Shares 29
BioGaia to Invest USD4.1 Million in Infant Bacterial Therapeutics 30
BioGaia Raises Additional USD0.52 Million from Infant Bacterial Therapeutics 31
BioGaia Acquires Additional 9% Stake in MetaboGen for USD0.43 Million 32
BioGaia Acquires Additional 12% Stake in MetaboGen for USD0.5 Million 33
BioGaia Acquires 15% Stake in MetaboGen for USD0.5 Million 34
BioGaia To Acquire Remaining 50% Stake In TwoPac For US$4.6 Million 35
BioGaia AB, Key Competitors 36
BioGaia AB, Key Employees 37
BioGaia AB, Other Locations 38
BioGaia AB, Subsidiaries 38

★海外企業調査レポート[BioGaia AB (BIOG B)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ascendance Biotechnology Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ascendance Biotechnology Inc (Ascendance), formerly Hepregen Corp is a healthcare products provider that offers cell based assay products. The company’s products include human HepatoMune kits, HepatoPac B-CLEAR transporter kits, human HepatoPac kits, rat HepatoPac kits, monkey HepatoPac kits …
  • Cardif Lux Vie S.A.:企業の戦略・SWOT・財務情報
    Cardif Lux Vie S.A. - Strategy, SWOT and Corporate Finance Report Summary Cardif Lux Vie S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Access Bio Inc (950130):医療機器:M&Aディール及び事業提携情報
    Summary Access Bio Inc (Access Bio) is a medical device company that research, develops, manufactures and markets in-vitro diagnostics tests, biosensor, and molecular diagnostic products. The company provides in vitro diagnostic technology such as immunochemical, biochemical and molecular products. …
  • Cohort Plc
    Cohort Plc - Strategy, SWOT and Corporate Finance Report Summary Cohort Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Splendid Metal Products Limited:企業の戦略・SWOT・財務情報
    Splendid Metal Products Limited - Strategy, SWOT and Corporate Finance Report Summary Splendid Metal Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Varian Medical Systems Inc (VAR):企業の財務・戦略的SWOT分析
    Varian Medical Systems Inc (VAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Twilio Inc (TWLO):企業の財務・戦略的SWOT分析
    Twilio Inc (TWLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • DEPObank – Banca Depositaria Italiana S.p.A:企業の戦略的SWOT分析
    DEPObank - Banca Depositaria Italiana S.p.A - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • National Shipping Company of Saudi Arabia (4030):石油・ガス:M&Aディール及び事業提携情報
    Summary National Shipping Company of Saudi Arabia (Bahri) is a joint stock shipping company, which purchases, charters and operates shipping vessels for the transportation of crude oil, liquefied petroleum gas (LPG), petrochemicals, general cargo, passengers and dry bulk. It operates a fleet of very …
  • Indian Oil Corporation Limited:企業の戦略・SWOT・財務情報
    Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Newpark Resources Inc (NR):石油・ガス:M&Aディール及び事業提携情報
    Summary Newpark Resources Inc (Newpark) offers fluid systems and services to oil and gas industry. The company offers drilling fluid products, solutions and services supporting directional, horizontal and deep water drilling projects. It grinds barite, which is used as a raw material in drilling flu …
  • TTEC Holdings Inc.:企業の戦略・SWOT・財務分析
    TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Endologix, Inc. (ELGX)-医療機器分野:企業M&A・提携分析
    Summary Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA p …
  • Puncak Niaga Holdings Bhd (PUNCAK):企業の財務・戦略的SWOT分析
    Puncak Niaga Holdings Bhd (PUNCAK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Otto Bock HealthCare GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Otto Bock HealthCare GmbH (Otto Bock), a group company of Otto Bock Holding GmbH & Co. KG, is a medical device company that manufactures and distributes prosthetic and orthotic devices. It also offers mobility and seating solutions for the physically disabled adults and children. The product …
  • AbbVie Inc (ABBV)-医療機器分野:企業M&A・提携分析
    Summary AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that carries out the research, development, manufacture and commercialization of advanced therapies to treat complex and serious diseases. The company focuses on providing drugs in immunology, cancer, neuroscience and virology …
  • Toyo Seikan Kaisha, Ltd.:企業の戦略・SWOT・財務情報
    Toyo Seikan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Toyo Seikan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • The Avascent Group:企業の戦略・SWOT・財務情報
    The Avascent Group - Strategy, SWOT and Corporate Finance Report Summary The Avascent Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • BioXcel Therapeutics Inc (BTAI):製薬・医療:M&Aディール及び事業提携情報
    Summary BioXcel Therapeutics Inc (BioXcel Therapeutics) a subsidiary of BioXcel Corp is a clinical stage biopharmaceutical company focused on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. Its pipeline product portfolio includes BXCL501, an ad …
  • R Pharm:製薬・医療:M&Aディール及び事業提携情報
    Summary R Pharm is a pharmaceutical company that develops and manufactures medicinal products. The company offers finished dosage forms, active pharmaceutical ingredients and biotechnological substances. It offers products in the therapeutic areas of oncology, hematology, immune diseases, antibiotic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆